Linagliptin: A Novel Methylxanthines Based Approved Dipeptidyl Peptidase-4 Inhibitor.
Authors: Agrawal R, Jain P, Dikshit SN
Abstract
Chemically, methylxanthine nucleus based Linagliptin (BI-1356, BI-1356-BS) is a dipeptidyl peptidase-IV inhibitor, which has been developed by Boehringer Ingelheim in association with Lilly for the treatment of Type-II Diabetes. Linagliptin was marketed by Lilly under the trade name Tradjenta and Trajenta. Linagliptin was approved as the once-daily dose by USFDA on 2 May 2011, for the treatment of Type-II Diabetes. Linagliptin 5mg once daily dose was approved based on a clinical trial program, which was conducted on approximately 4,000 adults with Type-II Diabetes. Linagliptin demonstrated statistically significant mean difference in HbA1c from placebo of up to 0.72 percent, when it was used monotherapically. In patients, who were not...
NHS 'paid £17 for pizza base'
Two prescription gluten-free pizza bases can cost the NHS as much as £35, BBC Newsnight has learned. (Source: BBC News | Health | UK Edition)div id=medwormpbiMedWorm Sponsor Message:/i/b Have a look at a href=http://www.thepsychologydaily.comThe Psychology Daily/a, the new psychology portal powered by MedWorm, with all the latest psychology news and research updated daily./p/div
